These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A small molecule inhibitor of p53-inducible protein phosphatase PPM1D. Yagi H; Chuman Y; Kozakai Y; Imagawa T; Takahashi Y; Yoshimura F; Tanino K; Sakaguchi K Bioorg Med Chem Lett; 2012 Jan; 22(1):729-32. PubMed ID: 22115592 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line. Kozakai Y; Kamada R; Kiyota Y; Yoshimura F; Tanino K; Sakaguchi K Bioorg Med Chem Lett; 2014 Dec; 24(24):5593-5596. PubMed ID: 25466181 [TBL] [Abstract][Full Text] [Related]
4. Targeting the PPM1D phenotype; 2,4-bisarylthiazoles cause highly selective apoptosis in PPM1D amplified cell-lines. Cheeseman MD; Faisal A; Rayter S; Barbeau OR; Kalusa A; Westlake M; Burke R; Swan M; van Montfort R; Linardopoulos S; Jones K Bioorg Med Chem Lett; 2014 Aug; 24(15):3469-74. PubMed ID: 24953599 [TBL] [Abstract][Full Text] [Related]
5. DNA damage signaling induced by the G-quadruplex ligand 12459 is modulated by PPM1D/WIP1 phosphatase. Douarre C; Mergui X; Sidibe A; Gomez D; Alberti P; Mailliet P; Trentesaux C; Riou JF Nucleic Acids Res; 2013 Apr; 41(6):3588-99. PubMed ID: 23396447 [TBL] [Abstract][Full Text] [Related]
6. Characterization of the active site and a unique uncompetitive inhibitor of the PPM1-type protein phosphatase PPM1D. Chuman Y; Yagi H; Fukuda T; Nomura T; Matsukizono M; Shimohigashi Y; Sakaguchi K Protein Pept Lett; 2008; 15(9):938-48. PubMed ID: 18991770 [TBL] [Abstract][Full Text] [Related]
8. WIP1 phosphatase as a potential therapeutic target in neuroblastoma. Richter M; Dayaram T; Gilmartin AG; Ganji G; Pemmasani SK; Van Der Key H; Shohet JM; Donehower LA; Kumar R PLoS One; 2015; 10(2):e0115635. PubMed ID: 25658463 [TBL] [Abstract][Full Text] [Related]
9. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Lu X; Nannenga B; Donehower LA Genes Dev; 2005 May; 19(10):1162-74. PubMed ID: 15870257 [TBL] [Abstract][Full Text] [Related]
10. PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38. Zhang M; Xu E; Zhang J; Chen X Oncogene; 2015 Nov; 34(48):5900-11. PubMed ID: 25823026 [TBL] [Abstract][Full Text] [Related]
11. PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53. Pärssinen J; Alarmo EL; Karhu R; Kallioniemi A Cancer Genet Cytogenet; 2008 Apr; 182(1):33-9. PubMed ID: 18328948 [TBL] [Abstract][Full Text] [Related]
12. [Function of Proto-oncogene Product PPM1D and Development of PPM1D Inhibitors for Cancer Chemotherapy]. Kamada R; Chuman Y; Kozakai Y; Sakaguchi K Seikagaku; 2015 Oct; 87(5):531-8. PubMed ID: 26638620 [No Abstract] [Full Text] [Related]
13. PPM1D regulates p21 expression via dephoshporylation at serine 123. Cao R; Zhang J; Zhang M; Chen X Cell Cycle; 2015; 14(4):641-7. PubMed ID: 25590690 [TBL] [Abstract][Full Text] [Related]
14. Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients. Zajkowicz A; Butkiewicz D; Drosik A; Giglok M; Suwiński R; Rusin M Br J Cancer; 2015 Mar; 112(6):1114-20. PubMed ID: 25742468 [TBL] [Abstract][Full Text] [Related]
15. Dual roles for the phosphatase PPM1D in regulating progesterone receptor function. Proia DA; Nannenga BW; Donehower LA; Weigel NL J Biol Chem; 2006 Mar; 281(11):7089-101. PubMed ID: 16352595 [TBL] [Abstract][Full Text] [Related]
16. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice. Nannenga B; Lu X; Dumble M; Van Maanen M; Nguyen TA; Sutton R; Kumar TR; Donehower LA Mol Carcinog; 2006 Aug; 45(8):594-604. PubMed ID: 16652371 [TBL] [Abstract][Full Text] [Related]
17. Knockdown of protein phosphatase magnesium-dependent 1 (PPM1D) through lentivirus-mediated RNA silencing inhibits colorectal carcinoma cell proliferation. Yin H; Yan Z; Liang Y; Liu B; Su Q Technol Cancer Res Treat; 2013 Dec; 12(6):537-43. PubMed ID: 23745790 [TBL] [Abstract][Full Text] [Related]
18. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Bulavin DV; Demidov ON; Saito S; Kauraniemi P; Phillips C; Amundson SA; Ambrosino C; Sauter G; Nebreda AR; Anderson CW; Kallioniemi A; Fornace AJ; Appella E Nat Genet; 2002 Jun; 31(2):210-5. PubMed ID: 12021785 [TBL] [Abstract][Full Text] [Related]
19. Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activity. Cheng A; Balczon R; Zuo Z; Koons JS; Walsh AH; Honkanen RE Cancer Res; 1998 Aug; 58(16):3611-9. PubMed ID: 9721869 [TBL] [Abstract][Full Text] [Related]
20. Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1. Yamaguchi H; Durell SR; Feng H; Bai Y; Anderson CW; Appella E Biochemistry; 2006 Nov; 45(44):13193-202. PubMed ID: 17073441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]